ÁÖÁ¦º°°Ë»ö
(current)
Å°¿öµå°Ë»ö
(±¸)µ¥ÀÌÅÍ°Ë»ö
¾÷µ¥ÀÌÆ®Á¤º¸
°ü·Ã»çÀÌÆ®
äßÀÇ Øóæ¹èþÛö
Cancer Immunotherapy
´ëÇѳ»°úÇÐȸÁö
1977³â 20±Ç 6È£ p.474 ~ p.480
±èµ¿Áý
(Kim Dong-Jip) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Å°¿öµå
KMID :
0882419770200060474
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
ÇÐȸ
µîÀçÀú³Î Á¤º¸
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
This paper discussed cancer immunotherapy including nonspecific immune therapy, active immunotherapy and passive immunotherapy.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°º¸ÇèÄÚµå